Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Ascending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00703-3671-01 00703-3671 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous June 8, 2018 In Use
00703-3671-03 00703-3671 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous July 31, 2012 Nov. 30, 2019 In Use
00703-3671-91 00703-3671 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Jan. 30, 2013 Oct. 31, 2017 In Use
00703-3671-93 00703-3671 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Jan. 30, 2013 Oct. 31, 2017 In Use
00703-3675-01 00703-3675 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Aug. 1, 2012 In Use
00703-3675-91 00703-3675 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intra-arterial, Intramuscular, Intrathecal, Intravenous Jan. 30, 2013 Feb. 28, 2017 In Use
00480-9772-01 00480-9772 Fludarabine Phosphate Fludarabine Phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 31, 2023 In Use
45963-0621-51 45963-0621 Fludarabine phosphate Fludarabine phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous March 2, 2017 June 30, 2023 No Longer Used
16729-0131-30 16729-0131 FLUDARABINE FLUDARABINE PHOSPHATE 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Nov. 22, 2022 In Use
61703-0124-40 61703-0124 Methotrexate Methotrexate 25.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intramuscular, Intrathecal, Intravenous, Subcutaneous Jan. 9, 2023 In Use
59923-0604-02 59923-0604 Fludarabine Phosphate Fludarabine Phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec. 31, 2019 In Use
50881-0006-03 50881-0006 Retifanlimab-dlwr ZYNYZ 25.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous March 22, 2023 In Use
00527-1242-02 00527-1242 Fludarabine Phosphate Fludarabine Phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec. 31, 2019 In Use
60505-6228-00 60505-6228 Bendamustine Hydrochloride Bendamustine Hydrochloride 25.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 26, 2023 In Use
82950-0012-01 82950-0012 Tovorafenib OJEMDA 25.0 mg/ml Chemotherapy Enzyme Inhibitor BRAF, CRAF ORAL April 30, 2024 In Use
55513-0057-01 55513-0057 Darbepoetin alfa Aranesp 25.0 ug/.42mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Feb. 18, 2011 In Use
55513-0057-04 55513-0057 Darbepoetin alfa Aranesp 25.0 ug/.42mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Aug. 26, 2006 In Use
55513-0002-01 55513-0002 Darbepoetin alfa Aranesp 25.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
55513-0002-04 55513-0002 Darbepoetin alfa Aranesp 25.0 ug/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous Sept. 11, 2006 In Use
00069-8140-20 00069-8140 Crizotinib Xalkori 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Aug. 26, 2011 In Use
16729-0051-53 16729-0051 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 7, 2017 In Use
40051-0609-11 40051-0609 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0609-12 40051-0609 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0609-13 40051-0609 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0609-51 40051-0609 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0609-52 40051-0609 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
40051-0609-53 40051-0609 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 1, 2016 In Use
47335-0893-21 47335-0893 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
47335-0893-74 47335-0893 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
47335-0893-75 47335-0893 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
47335-0893-80 47335-0893 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
47335-0893-87 47335-0893 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 13, 2014 In Use
54868-5354-00 54868-5354 Temozolomide Temodar 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 13, 2006 In Use
64144-0506-01 64144-0506 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 13, 2016 In Use
65162-0806-51 65162-0806 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 3, 2015 In Use
00078-0671-19 00078-0671 Lapatinib TYKERB 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Aug. 3, 2016 In Use
00173-0752-00 00173-0752 Lapatinib TYKERB 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral March 16, 2007 Nov. 30, 2017 No Longer Used
00904-6948-04 00904-6948 Abiraterone Acetate Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Nov. 23, 2018 In Use
16714-0963-01 16714-0963 Abiraterone Acetate Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 19, 2020 In Use
68180-0801-36 68180-0801 lapatinib Lapatinib 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Oral Sept. 29, 2020 In Use
72606-0566-01 72606-0566 Abiraterone acetate Abiraterone acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Jan. 7, 2020 In Use
69539-0049-92 69539-0049 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral July 10, 2019 In Use
68001-0489-07 68001-0489 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Feb. 26, 2021 In Use
72205-0030-92 72205-0030 Abiraterone acetate Abiraterone 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral July 10, 2019 In Use
68462-0135-08 68462-0135 Abiraterone acetate Abiraterone acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Oct. 16, 2019 In Use
42737-0106-05 42737-0106 temozolomide TEMOZOLOMIDE 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 31, 2018 Jan. 24, 2019 In Use
43975-0257-05 43975-0257 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral July 13, 2016 In Use
51862-0088-51 51862-0088 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Oct. 10, 2016 Sept. 30, 2019 No Longer Used
67877-0542-07 67877-0542 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral April 28, 2017 In Use
00093-7602-57 00093-7602 Temozolomide Temozolomide 250.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 12, 2013 Oct. 31, 2018 In Use

Found 10,000 results in 11 millisecondsExport these results